Changes in the prescription pattern of antipsychotics for schizophrenic outpatients after the implementation of a global budgeting program
- PMID: 24863739
- PMCID: PMC7105039
- DOI: 10.1016/j.jcma.2014.03.004
Changes in the prescription pattern of antipsychotics for schizophrenic outpatients after the implementation of a global budgeting program
Abstract
Background: A hospital-based global budget (GB) program was implemented by the Taiwan Bureau of National Health Insurance (TBNHI) to control the rising costs of medical care. We investigated whether the introduction of the GB program affected prescriptions for second-generation antipsychotics (SGAs) for schizophrenic outpatients in public and private medical and psychiatric centers.
Methods: The prescription data of schizophrenic outpatients treated between 2001 and 2004 were retrieved from the TBNHI database, which included outpatients who were diagnosed as having schizophrenia during the period from 1996 to 2001. Because the new health insurance policy may have had a lag effect on physicians' decision regarding SGA prescription, we used January 2004 as the timepoint to divide the data, which was 6 months after GB implementation. Thus, data from the 6-month period immediately after the GB implementation were included in the pre-GB period. Second-generation antipsychotics included in the study were clozapine, risperidone, olanzapine, quetiapine, ziprasidone, zotepin, and amisulpride.
Results: After January 2004, the proportion of SGA use in outpatient departments did not show an upward trend, as had been observed in the pre-GB period, which appeared at a staggering pace lasting for 12 months (p = 0.0004). Compared with medical centers, SGA expenditures in the psychiatric centers were less affected in the GB period (p < 0.0001). Compared to the private sector, the SGA expenditures in the public sector were less affected in the GB period (p < 0.019).
Conclusion: We concluded that the GB implementation reduced SGA expenditures significantly. The extent of influence varied among hospitals (i.e., public versus private, medical versus psychiatric centers), which was most likely caused by financial factors.
Keywords: National Health Insurance; global budgeting; schizophrenia.
Copyright © 2014. Published by Elsevier B.V.
Figures




Similar articles
-
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Hum Psychopharmacol. 2011. PMID: 23055416 Review.
-
Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.Pharmacopsychiatry. 2009 Mar;42(2):66-71. doi: 10.1055/s-0028-1103293. Epub 2009 Mar 23. Pharmacopsychiatry. 2009. PMID: 19308881
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting.J Basic Clin Physiol Pharmacol. 2019 Dec 14;30(6):/j/jbcpp.2019.30.issue-6/jbcpp-2019-0289/jbcpp-2019-0289.xml. doi: 10.1515/jbcpp-2019-0289. J Basic Clin Physiol Pharmacol. 2019. PMID: 31837257
-
National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom.Pharmacoepidemiol Drug Saf. 2012 Feb;21(2):161-9. doi: 10.1002/pds.2213. Epub 2011 Aug 19. Pharmacoepidemiol Drug Saf. 2012. PMID: 21858898
Cited by
-
Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan.Neuropsychiatr Dis Treat. 2018 Mar 8;14:725-732. doi: 10.2147/NDT.S161186. eCollection 2018. Neuropsychiatr Dis Treat. 2018. PMID: 29563800 Free PMC article.
References
-
- Hoblyn J., Noda A., Yesavage J.A., Brooks J.O., 3rd, Sheikh J., Lee T. Factors in choosing atypical antipsychotics: toward understanding the bases of physicians' prescribing decisions. J Psychiatr Res. 2006;40:160–166. - PubMed
-
- Lee Y.C., Yang M.C., Huang Y.T., Liu C.H., Chen S.B. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan. 1996–2003. Pharmacoeconomics. 2006;24:891–902. - PubMed
-
- Eisenberg J.M. Doctors' decisions and the cost of medical care: the reason for doctors' practice patterns and how to change them. 1st ed. Health Administration Press; Ann Arbor, MI: 1986.
-
- Aas I.H. Incentives and financing methods. Health Policy. 1995;34:205–220. - PubMed
-
- Cheng S.H., Chen C.C., Chang W.L. Hospital response to a global budget program under universal health insurance in Taiwan. Health Policy. 2009;92:158–164. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical